Guo et al. reported significant CD93 overexpression in glioblastoma multiforme (GBM), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), cholangiocarcinoma (CHOL), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), kidney renal clear cell carcinoma (KIRC), acute myeloid leukemia (LAML), HNSCCs, testicular germ cell tumors (TGCT), and skin cutaneous melanoma (SKCM). This evidence concerns the gene CD93 and gastric adenocarcinoma.